文献速递妇科

衰弱是晚期卵巢癌女性化疗剂量不足的决定因素

Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2020-06-06

研究纳入2003年1月2日至2011年12月30日期间接受初次肿瘤细胞减灭术的上皮性卵巢癌(EOC)女性,评估衰弱与辅助化疗实施的关系。衰弱者术后未接受化疗的比例更高(26.7% vs 14.2%,p=0.001),且更少完成6个周期化疗(75.9% vs 93.6%,p=0.008)。调整年龄后,衰弱与更短的无进展生存(HR 1.58,95%CI 0.99-2.50)和总生存(HR 2.14,95%CI 1.35-3.41)相关。

要点

  • 衰弱者术后未接受化疗的比例为26.7%,非衰弱者为14.2%(p=0.001)。
  • 衰弱者完成6周期化疗的比例为75.9%,非衰弱者为93.6%(p=0.008)。
  • 以RDI 85%为界,衰弱者卡铂足量比例为15.8%,非衰弱者为66.2%(p<0.001)。

核心结论

  • 衰弱的上皮性卵巢癌女性在初次肿瘤细胞减灭术后更少接受化疗或接受最佳剂量化疗,且无治疗相关毒性证据。
  • 衰弱患者无进展生存和总生存更短。
  • 需要进一步研究探讨衰弱、化疗与生存之间的关联。

研究设计与样本

  • 纳入2003年1月2日至2011年12月30日期间因IIIC/IV期上皮性卵巢癌接受初次肿瘤细胞减灭术、在本机构接受辅助化疗且有数据计算衰弱缺陷指数的女性。
  • 衰弱定义为衰弱缺陷指数≥0.15。
  • 接受化疗的169例女性中,17.2%(29/169)为衰弱。
  • 化疗相对剂量强度(RDI)按实际给药剂量占标准剂量的百分比计算,采用Wilcoxon秩和检验比较衰弱与非衰弱组。

主要发现

  • 初次肿瘤细胞减灭术后未接受化疗在衰弱组为26.7%,非衰弱组为14.2%(p=0.001)。
  • 衰弱组年龄更大(均值67.9 vs 62.3岁,p=0.01),BMI更高(均值29.6 vs 25.7 kg/m2,p=0.003)。
  • 衰弱组完成6周期化疗的比例为75.9%,非衰弱组为93.6%(p=0.008)。
  • 以RDI 85%为界,衰弱组卡铂足量比例为15.8%,非衰弱组为66.2%(p<0.001);紫杉醇足量比例为57.9% vs 80.5%(p=0.07)。
  • 剂量延迟(34.5% vs 42.1%)、剂量减少(65.5% vs 68.6%)和严重中性粒细胞减少(44.8% vs 39.3%)两组无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究探讨衰弱、化疗与生存之间的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the relationship between frailty and chemotherapy delivery among women with epithelial ovarian cancer (EOC). METHODS: We included women who underwent primary debulking surgery (PDS) for stage IIIC/IV EOC between 1/2/2003 and 12/30/2011, received adjuvant chemotherapy at our institution, and had data available to calculate a frailty deficit index. Frailty was defined as a frailty deficit index ≥0.15. Relative dose intensity (RDI) of chemotherapy was calculated as the percentage of the standard dose that was administered, and compared between frail and non-frail using the Wilcoxon rank-sum test. RESULTS: Failure to receive chemotherapy following PDS was twice as common among frail vs. non-frail women (26.7% vs 14.2%, p = 0.001). Of the 169 women who received chemotherapy at our institution, 17.2% (29/169) were frail. Frail women were older (mean, 67.9 vs 62.3 years, p = 0.01), had higher BMI (mean, 29.6 vs 25.7 kg/m2, p = 0.003), and were less likely to complete 6 cycles of chemotherapy (75.9 vs. 93.6%, p = 0.008). Using an RDI cutoff of 85%, frail women were less likely to have adequate doses of carboplatin (15.8 vs. 66.2%, p < 0.001) and paclitaxel (57.9 vs. 80.5%, p = 0.07) despite no differences in dose delays (34.5 vs. 42.1%), dose reductions (65.5 vs. 68.6%), and severe neutropenia (44.8 vs. 39.3%). After adjusting for age, frailty was associated with shorter progression-free (HR 1.58, 95% CI: 0.99-2.50) and overall survival (HR 2.14, 95% CI: 1.35-3.41). CONCLUSION: Frail women with EOC were less likely to receive chemotherapy or the optimal dose of chemotherapy after PDS despite no evidence of treatment-related toxicity. Frail EOC patients demonstrated shorter progression-free and overall survival. Further studies are needed to explore the association between frailty, chemotherapy, and survival.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Narasimhulu DM, McGree ME, Weaver AL, et al. Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer. Gynecol Oncol. 2020. PMID: 32518016. doi:10.1016/j.ygyno.2020.05.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。